Civica Rx, Xellia Pharmaceuticals Sign Supply Pact for Antibiotics

By Patricia Van Arnum - DCAT Editorial Director

May 16, 2019

Civica Rx, a pharmaceutical company providing drugs in shortage, and Xellia Pharmaceuticals, a specialty pharmaceutical company specializing in anti-infectives, have signed a product supply agreement under which Xellia will manufacture essential antibiotics, including vancomycin and daptomycin, for Civica’s member health systems.

Civica was established in 2018 to reduce chronic generic drug shortages as a non-profit, non-stock corporation committed to stabilizing the supply of essential generic medications in a hospital setting.The company is headed by President and Chief Executive Officer Martin VanTrieste, formerly Senior Vice President of Quality at Amgen.  

Xellia becomes Civica’s first supplier partner to produce these antibiotics in short supply in US hospitals. Civica has committed to partnering with suppliers to deliver 14 essential generic medications this year.

Xellia, headquartered in Copenhagen, Denmark, is expanding its manufacturing and sales capabilities within the US. The company produces its own active pharmaceutical ingredients as well as finished injectable drug products for bacterial and fungal infections.

Xellia will make medications for Civica under Xellia’s abbreviated new drug application (ANDA) and Civica labeling and new drug code (NDC).

Civica aims to stabilize the supply of antibiotics, anesthetics, cardiac medications, pain management medications, and other essential sterile injectable medicines used in hospitals. It is pursuing a three-pronged product supply strategy: (1) working with multiple generic drug manufacturers (with Xellia as its first) that have US Food and Drug Adminstration approved manufacturing facilities and capacity to produce Civica-labeled generic drugs, allowing manufacturers to re-enter the market or increase existing capacity; (2) developing and acquiring ANDAs for generic drugs and working with contract manufacturing organizations to produce Civica medications; and acquiring and building Civica manufacturing facilities using Civica’s ANDAs.

Source: Xellia Pharmaceuticals and Civica Rx